India, March 3 -- Voyager Therapeutics, Inc. (VYGR) Monday announced positive topline data from its single ascending dose (SAD) study of VY7523 developed for the treatment of Alzheimers disease (AD).
The study was to evaluate safety, tolerability, and dose-proportional pharmacokinetics (PK) of VY7523 in healthy volunteers.
Voyager has initiated a multiple ascending dose (MAD) study of VY7523 in patients with early AD with data expected in the second half of 2026.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....